Ari Ristimäki

17.8k total citations · 3 hit papers
197 papers, 10.6k citations indexed

About

Ari Ristimäki is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Ari Ristimäki has authored 197 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 60 papers in Molecular Biology and 55 papers in Surgery. Recurrent topics in Ari Ristimäki's work include Inflammatory mediators and NSAID effects (46 papers), Genetic factors in colorectal cancer (36 papers) and Gastric Cancer Management and Outcomes (21 papers). Ari Ristimäki is often cited by papers focused on Inflammatory mediators and NSAID effects (46 papers), Genetic factors in colorectal cancer (36 papers) and Gastric Cancer Management and Outcomes (21 papers). Ari Ristimäki collaborates with scholars based in Finland, United States and Sweden. Ari Ristimäki's co-authors include Timothy Hla, Caj Haglund, Kirsi Narko, Kirsi Saukkonen, Alexandra Thiel, Anna Sivula, Heikki Joensuu, Mikael Lundin, Johan Lundin and Jorma Isola and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ari Ristimäki

188 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

2002 672 citations Ari Ristimäki, Johan Lundin et al. profile →
Expression of cyclooxygenase-2 in human lung carcinoma.

1998 626 citations Kirsi Saukkonen, Ari Ristimäki et al. profile →
Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

1994 572 citations Ari Ristimäki et al. profile →

Peers

Countries citing papers authored by Ari Ristimäki

Since Specialization

Citations

This map shows the geographic impact of Ari Ristimäki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari Ristimäki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari Ristimäki more than expected).

Fields of papers citing papers by Ari Ristimäki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari Ristimäki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari Ristimäki. The network helps show where Ari Ristimäki may publish in the future.

Co-authorship network of co-authors of Ari Ristimäki

This figure shows the co-authorship network connecting the top 25 collaborators of Ari Ristimäki. A scholar is included among the top collaborators of Ari Ristimäki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari Ristimäki. Ari Ristimäki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel insights into tumorigenesis revealed by molecular analysis of Lynch syndrome cases with multiple colorectal tumors 2024 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Ari Ristimäki, Maarit Ahtiainen, Jukka‐Pekka Mecklin, Païvi Peltomäki	1
2	Optimal lymph node yield in oesophagectomy for oesophageal cancer: a nationwide population-based study 2024 ·European Journal of Cardio-Thoracic Surgery ·Mikko Uimonen, Olli Helminen, Eero Sihvo, Joonas H. Kauppila, (unknown), Mika Helmiö, Heikki Huhta, (unknown), Vesa Koivukangas, Arto Kokkola, Simo Laine, Elina Lietzén, Sanna Meriläinen, (unknown), Tuomo Rantanen, Ari Ristimäki, Jari Räsänen, Juha Saarnio, (unknown), (unknown), Antti Valtola	3
3	Pre-Surgical Endoscopic Biopsies Are Representative of Esophageal and Esophago-Gastric Junction Adenocarcinoma Histologic Classes and Survival Risk 2024 ·Cancers ·Alessandro Gambella, Roberto Fiocca, Marialuisa Lugaresi, Antonietta D’Errico, Deborah Malvi, Paola Spaggiari, Anna Tomezzoli, Luca Albarello, Ari Ristimäki, Luca Bottiglieri, Elena Bonora, Kausilia K. Krishnadath, (unknown), Riccardo Rosati, Uberto Fumagalli Romario, (unknown), Jari Räsänen, Sandro Mattioli, Federica Grillo, Luca Mastracci	0
4	N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer 2023 ·Cancers ·(unknown), Pirjo Nummela, Annamari Heiskanen, Matilda Holm, Sadia Zafar, Mia Kero, Caj Haglund, Tero Satomaa, Soili Kytölä, Ari Ristimäki	1
5	N-glycosylation in non-invasive and invasive intraductal papillary mucinous neoplasm 2023 ·Scientific Reports ·(unknown), Pirjo Nummela, Tero Satomaa, Annamari Heiskanen, Jukka O. Hiltunen, Tuomas Kaprio, Hanna Seppänen, Jaana Hagström, Harri Mustonen, Ari Ristimäki, Caj Haglund	0
6	Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model 2023 ·Molecular Cancer Therapeutics ·Héctor J. Monzó, (unknown), Marko Hyytiäinen, (unknown), (unknown), Lidia Moyano‐Galceran, (unknown), (unknown), Pirjo Laakkonen, Ari Ristimäki, Joseph W. Carlson, Kaisa Lehti, Sahar Salehi, Pauli Puolakkainen, Caj Haglund, Hanna Seppänen, Sirpa Leppä, Päivi M. Ojala	14
7	Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia 2023 ·Leukemia ·(unknown), Taina T. Nieminen, (unknown), (unknown), Mika Kontro, (unknown), Matti Kankainen, Ari Ristimäki, Markus J. Mäkinen, Päivi Lahermo, Caroline A. Heckman, Janna Saarela, Milla Salonen, Anna Lepistö, Heikki Järvinen, Jukka‐Pekka Mecklin, Outi Kilpivaara, Ulla Wartiovaara‐Kautto, Kimmo Porkka, Païvi Peltomäki	1
8	Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype 2022 ·Molecular Cancer Therapeutics ·Anna N. Cvrljevic, (unknown), Kaisa Huhtinen, Tove J. Grönroos, Camilla Böckelman, Heini Lassus, Ralf Bützow, Caj Haglund, Katja Kaipio, (unknown), Teemu D. Laajala, Denise C. Connolly, Ari Ristimäki, Olli Carpén, Jeroen Pouwels, Jukka Westermarck	3
9	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer 2021 ·Scientific Reports ·(unknown), Ari Ristimäki, Harri Mustonen, (unknown), Jaana Hagström, Caj Haglund, Hanna Seppänen	3
10	Association between chronic pancreatitis and pancreatic cancer: A 10‐year retrospective study of endoscopically treated and surgical patients 2020 ·International Journal of Cancer ·(unknown), Marianne Udd, Harri Mustonen, Ari Ristimäki, Caj Haglund, Hanna Seppänen, Leena Kylänpää	19
11	Cohort profile: a nationwide population-based retrospective assessment of oesophageal cancer in the Finnish National Esophago-Gastric Cancer Cohort (FINEGO) 2020 ·BMJ Open ·(unknown), Jari Räsänen, Juha Saarnio, (unknown), (unknown), Tuomo Rantanen, Antti Valtola, Pasi Ohtonen, (unknown), Arto Kokkola, (unknown), Tuomo J. Karttunen, (unknown), Ari Ristimäki, Simo Laine, Eero Sihvo, Joonas H. Kauppila	4
12	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study 2019 ·Histopathology ·(unknown), J. Han van Krieken, Gert De Hertogh, Gerald Höefler, Anca Oniscu, (unknown), Wilko Weichert, Caterina Marchiò, Ari Ristimäki, Aleš Ryška, Jean‐Yves Scoazec, Elisabeth Dequeker	16
13	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib 2017 ·Clinical Genitourinary Cancer ·Katriina Peltola, (unknown), (unknown), Heikki Joensuu, (unknown), Ari Ristimäki, Petri Bono	20
14	Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis 2015 ·Journal of Surgical Oncology ·Laura Koskenvuo, Païvi Peltomäki, Laura Renkonen‐Sinisalo, Annette Gylling, Taina T. Nieminen, Ari Ristimäki, Anna Lepistö	30
15	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study 2011 ·Breast Cancer Research ·Harri Sihto, Johan Lundin, Mikael Lundin, Terho Lehtimäki, Ari Ristimäki, Kaija Holli, Liisa Sailas, Vesa Kataja, Taina Turpeenniemi‐Hujanen, Jorma Isola, Päivi Heikkilä, Heikki Joensuu	181
16	Treatment of cancer patients with capsid modified double controlled oncolytic adenovirus Ad5/3-Cox2L-D24 2008 ·Cancer Research ·Sari Pesonen, Petri Nokisalmi, Ari Ristimäki, Teemu Kantola, Gerd Bauerschmitz, Anna Kanerva, Timo Joensuu, Akseli Hemminki	1
17	Increased Expression of Cyclooxygenase-2 in Malignant Pheochromocytomas 2001 ·The Journal of Clinical Endocrinology & Metabolism ·Kaisa Salmenkivi, Caj Haglund, Ari Ristimäki, Johanna Arola, Päivi Heikkilä	61
18	Expression of Cyclooxygenase-2 in Human Transitional Cell Carcinoma of the Urinary Bladder 2001 ·American Journal Of Pathology ·Ari Ristimäki, Outi Nieminen, Kirsi Saukkonen, Kristina Hotakainen, Stig Nordling, Caj Haglund	122
19	Vascular Endothelial Growth Factor in Human Preterm Lung 1999 ·American Journal of Respiratory and Critical Care Medicine ·Patrik Lassus, Ari Ristimäki, Olavi Ylikorkala, Lasse Viinikka, Sture Andersson	119
20	Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation 1998 ·Journal of Thrombosis and Haemostasis ·Ulla Wartiovaara, Petri Salvén, Hanna Mikkola, Riitta Lassila, Jaakko Kaukonen, Vladimir Joukov, Arto Orpana, Ari Ristimäki, Markku Heikinheimo, Heikki Joensuu, Kari Alitalo, Aarno Palotie	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact